HPV16 Oncoproteins Induce MMPs/RECK-TIMP-2 Imbalance in Primary Keratinocytes: Possible Implications in Cervical Carcinogenesis

Cervical cancer is the third most common cancer in women worldwide. Persistent infection with high-risk HPV types, principally HPV16 and 18 is the main risk factor for the development of this malignancy. However, the onset of invasive tumor occurs many years after initial exposure in a minority of infected women. This suggests that other factors beyond viral infection are necessary for tumor establishment and progression. Tumor progression is characterized by an increase in secretion and activation of matrix metalloproteinases (MMPs) produced by either the tumor cells themselves or tumor-associated fibroblasts or macrophages. Increased MMPs expression, including MMP-2, MMP-9 and MT1-MMP, has been observed during cervical carcinoma progression. These proteins have been associated with degradation of ECM components, tumor invasion, metastasis and recurrence. However, few studies have evaluated the interplay between HPV infection and the expression and activity of MMPs and their regulators in cervical cancer. We analyzed the effect of HPV16 oncoproteins on the expression and activity of MMP-2, MMP-9, MT1-MMP, and their inhibitors TIMP-2 and RECK in cultures of human keratinocytes. We observed that E7 expression is associated with increased pro-MMP-9 activity in the epithelial component of organotypic cultures, while E6 and E7 oncoproteins co-expression down-regulates RECK and TIMP-2 levels in organotypic and monolayers cultures. Finally, a study conducted in human cervical tissues showed a decrease in RECK expression levels in precancer and cancer lesions. Our results indicate that HPV oncoproteins promote MMPs/RECK-TIMP-2 imbalance which may be involved in HPV-associated lesions outcome.

[1]  B. Karlan,et al.  Knockdown of ovarian cancer amplification target ADRM1 leads to downregulation of GIPC1 and upregulation of RECK , 2011, Genes, chromosomes & cancer.

[2]  B. Akgül,et al.  The E2 protein of human papillomavirus type 8 increases the expression of matrix metalloproteinase-9 in human keratinocytes and organotypic skin cultures , 2011, Medical Microbiology and Immunology.

[3]  Q. Dong,et al.  Expression of the reversion‐inducing cysteine‐rich protein with Kazal motifs and matrix metalloproteinase‐14 in neuroblastoma and the role in tumour metastasis , 2010, International journal of experimental pathology.

[4]  S. Taboga,et al.  RECK‐mediated inhibition of glioma migration and invasion , 2010, Journal of cellular biochemistry.

[5]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[6]  K. Münger,et al.  Oncogenic activities of human papillomaviruses. , 2009, Virus research.

[7]  Wen-li Ma,et al.  Microarray Analysis Identifies Differentially Expressed Genes Induced by Human Papillomavirus Type 18 E6 Silencing RNA , 2009, International Journal of Gynecologic Cancer.

[8]  H. Kitayama,et al.  The membrane-anchored metalloproteinase regulator RECK stabilizes focal adhesions and anterior–posterior polarity in fibroblasts , 2009, Oncogene.

[9]  H. Howie,et al.  Papillomavirus E6 proteins. , 2009, Virology.

[10]  H. Osada,et al.  RECK negatively regulates matrix metalloproteinase-9 transcription. , 2009, Cancer research.

[11]  S. Yoshida,et al.  Ras Modifies Proliferation and Invasiveness of Cells Expressing Human Papillomavirus Oncoproteins , 2008, Journal of Virology.

[12]  Craig Murdoch,et al.  Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. , 2008, Neoplasia.

[13]  W. Stetler-Stevenson.  The tumor microenvironment: regulation by MMP-independent effects of tissue inhibitor of metalloproteinases-2 , 2008, Cancer and Metastasis Reviews.

[14]  David M. Thomas,et al.  RECK—a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer , 2007, Cancer and Metastasis Reviews.

[15]  M. Sogayar,et al.  Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. , 2006, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[16]  W. Stetler-Stevenson,et al.  TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118 , 2006, Oncogene.

[17]  D. Santini,et al.  Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (TIMP-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN. , 2006, Anticancer research.

[18]  Bin Nan,et al.  Expression of membrane type 1 matrix metalloproteinase is associated with cervical carcinoma progression and invasion. , 2005, Cancer research.

[19]  R. Ball,et al.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues , 2005, British Journal of Cancer.

[20]  W. Stetler-Stevenson,et al.  Tissue Inhibitors of Metalloproteinase 2 Inhibits Endothelial Cell Migration through Increased Expression of RECK , 2004, Cancer Research.

[21]  T. R. Broker,et al.  HPV-18 confers resistance to TNF-α in organotypic cultures of human keratinocytes , 2004 .

[22]  H. Matsumoto,et al.  The Membrane-Anchored Matrix Metalloproteinase (MMP) Regulator RECK in Combination with MMP-9 Serves as an Informative Prognostic Indicator for Colorectal Cancer , 2004, Clinical Cancer Research.

[23]  H. Wada,et al.  Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. , 2004, European journal of cancer.

[24]  E. Baracat,et al.  Comparative study of MMP-2 (matrix metalloproteinase 2) immune expression in normal uterine cervix, intraepithelial neoplasias, and squamous cells cervical carcinoma. , 2004, American journal of obstetrics and gynecology.

[25]  W. Hung,et al.  RECK is a target of Epstein–Barr virus latent membrane protein 1 , 2003, Oncogene.

[26]  S. Chow,et al.  Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. , 2003, Cancer research.

[27]  P. Span,et al.  Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs , 2003, Cancer.

[28]  M. Imamura,et al.  RECK expression in pancreatic cancer: its correlation with lower invasiveness and better prognosis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  D. Karunagaran,et al.  Changes in matrix metalloproteinases and their endogenous inhibitors during tumor progression in the uterine cervix , 2003, Journal of Cancer Research and Clinical Oncology.

[30]  M. Sogayar,et al.  Transcriptional control of the RECK metastasis/angiogenesis suppressor gene. , 2002, Cancer detection and prevention.

[31]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[32]  P. Flemming,et al.  MMP-1 and MMP-2 in the cervix uteri in different steps of malignant transformation--an immunohistochemical study. , 2002, Gynecologic oncology.

[33]  T. Rohan,et al.  Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. , 2001, JAMA.

[34]  David B. Alexander,et al.  The Membrane-Anchored MMP Inhibitor RECK Is a Key Regulator of Extracellular Matrix Integrity and Angiogenesis , 2001, Cell.

[35]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[36]  S. Arii,et al.  RECK gene expression in hepatocellular carcinoma: Correlation with invasion‐related clinicopathological factors and its clinical significance , 2001, Hepatology.

[37]  D. DiMaio,et al.  Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. DiMaio,et al.  Rapid induction of senescence in human cervical carcinoma cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Z. Werb,et al.  The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter , 2000, Oncogene.

[40]  K. Lehti,et al.  MMP2 activation by collagen I and concanavalin A in cultured human hepatic stellate cells , 1999, Hepatology.

[41]  Y Ikawa,et al.  Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Nuovo,et al.  Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. , 1995, Cancer research.

[43]  Claudia Wickenhauser,et al.  Molecular pathobiology of human cervical high-grade lesions: paracrine STAT3 activation in tumor-instructed myeloid cells drives local MMP-9 expression. , 2011, Cancer research.

[44]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[45]  L. Chow,et al.  HPV-18 confers resistance to TNF-alpha in organotypic cultures of human keratinocytes. , 2004, Virology.